What Ascor L 500 Treats: Main Uses and Benefits

Ascor L 500 is primarily used for the clinical management of scurvy, the most severe form of Vitamin C deficiency. Its therapeutic purpose supports the process of correcting the nutritional status, which generally contributes to easing the systemic symptoms associated with the shortfall, such as severe fatigue, profound weakness, and deficiency-related joint pain.

---

The injection is specifically applied across conditions presenting with acute episodes and is relevant for managing symptom clusters like hemorrhagic manifestations, symptoms related to tissue fragility, and systemic weakness. This supportive benefit may assist in easing the symptoms of abnormal bleeding and supports the process of tissue repair in cases of slow-healing wounds.

“The medication is generally relevant for patient groups who cannot reliably utilize Vitamin C supplements taken by mouth, such as individuals with severe malabsorption syndromes or those in acute care unable to tolerate oral intake.”

Its application in these scenarios helps provide nutrients to the system, supporting the process of addressing the deficiency in acute clinical scenarios.

Quick Fact: Relief for Deficiency Symptoms
Primary Indication: Clinical management of scurvy and severe Vitamin C deficiency.
Symptom Focus: Easing symptoms of abnormal bleeding, bruising, and severe fatigue.
Scenario: Used when oral intake is compromised (e.g., malabsorption or severe vomiting).

Regulatory References

1. Official FDA Labeling for Ascorbic Acid Injection (ASCOR)

Who can and cannot use Ascor L 500 — Official Regulatory Information

The eligibility for Ascor L 500 (Ascorbic Acid Injection) is defined by regulatory documents based on patient age, pre-existing conditions, and physiological status.

Eligibility Scope

Eligibility Category	Regulatory Requirement / Population Group
Populations allowed	Adult patients and pediatric patients age 5 months and older.
Populations contraindicated	Known hypersensitivity to any component (per international labeling). None (per U.S. FDA labeling).
Age-related restrictions	Use is not indicated in infants under 5 months of age.

Eligibility-Related Restrictions

Use of the medicine requires special caution in several high-risk populations, as defined in regulatory warnings and precautions:

• Renal Status: Patients with renal disease, severe renal impairment, or a history of oxalate kidney stones are at increased risk for oxalate nephropathy.
• Genetic Conditions: Individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of severe hemolysis, and a reduced dose is recommended to prevent this.
• Hematological Conditions: Use of large doses is restricted in patients with conditions like haemochromatosis or thalassæmia due to the risk of increased iron absorption.
• Age Subgroups: Geriatric patients and pediatric patients less than 2 years of age are listed as populations with increased risk for oxalate nephropathy.

Use in pregnant and lactating women is restricted, with official guidance stating they should not exceed the U.S. Recommended Dietary Allowance (RDA) for their condition.

Interaction Map: Interactions with other medicines and products — official regulatory information for Ascor L 500

---

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Antibiotics, Phenothiazines, Oral Contraceptives, Oral Anticoagulants, Urine Acidifiers, Iron Chelators, and Oxidation-Reduction Based Laboratory Tests.
Specific interacting medicines (if explicitly listed)	Erythromycin, Kanamycin, Bleomycin, Fluphenazine, Amphetamine, Tricyclic Anti-depressants, Warfarin, Desferrioxamine, and Ethinyloestradiol.
Mechanistic basis of interactions (only if stated in label)	Altered renal excretion due to urine acidification; chemical inactivation; decreased activity; and increased urinary excretion of the co-administered drug.
Timing-based interaction rules (if applicable)	Laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion to avoid inaccurate results (e.g., false negatives).
Population-specific interaction notes (if applicable)	In patients with kidney failure, high-dose Vitamin C may interact similarly to oral citrate in leading to encephalopathy when combined with aluminum antacids.
Interaction-related restrictions	Bleomycin is documented as being inactivated in vitro.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Documentation
Interaction severity classification (as defined in official documents)	Interactions include those resulting in decreased activity, lowered serum concentrations, and those necessitating continuation of standard monitoring.
Regulatory basis (EMA / FDA / etc.)	U.S. Food and Drug Administration / Medsafe.
Interaction-context constraints (as defined in official documents)	Interference with diagnostic procedures requires a mandatory 24-hour separation rule. Co-treatment with Desferrioxamine is associated with increased iron deposition in visceral organs.

---

Resulting Interaction Structure

Official interaction statements:

• Ascorbic acid may decrease the activities of certain antibiotics (e.g., Erythromycin) and inactivate Bleomycin in vitro.
• Ascorbic acid causes urine acidification, which lowers serum concentrations of Amphetamine and certain Tricyclic Anti-depressants by accelerating their renal excretion.
• Fluphenazine plasma concentrations are decreased with concurrent use.
• High doses of ascorbic acid increase the bioavailability of Ethinyloestradiol and have been associated with increased iron deposition in visceral organs when used with Desferrioxamine.
• Alcohol consumption is documented to reduce ascorbic acid levels.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure based primarily on its reducing properties, which decrease the activity of certain co-administered medicinal products, and its effect on urine pH, which results in altered systemic exposure (lower serum concentrations) of specific medicines. A mandatory timing restriction is imposed on certain laboratory tests to prevent false results, and specific constraints are noted for co-administration with iron-chelating agents due to officially documented effects on iron mobilization.

Cofactor Function in Structural and Signaling Pathways

The primary mechanism of Ascorbic Acid is its role as a required cofactor and electron donor for crucial metalloenzymes, particularly the α-ketoglutarate-dependent dioxygenases. By maintaining the active ferrous iron ( Fe^2+) in these enzymes, it enables the hydroxylation of proline and lysine, which is necessary for stable collagen formation. This cofactor function is also required for the synthesis of the neurotransmitter norepinephrine via Dopamine β-monooxygenase. This molecular action governs biosynthetic capacity for connective tissue stabilization (e.g., vascular structures) and systemic catecholamine signaling.

Modulation of Cellular Redox State

The molecule functions as a water-soluble reducing agent that neutralizes Reactive Oxygen Species (ROS). By donating electrons, it reduces the oxidative modification of proteins, lipids, and DNA. This mechanism modulates the cellular redox state, influencing the operation of metabolic processes in tissues, including immune cells and the adrenal glands. Furthermore, its reducing action facilitates the absorption and mobilization of iron, influencing the operational state of iron-dependent enzyme function throughout the body.

Ascor L 500 is administered exclusively via the parenteral route as a slow intravenous (IV) infusion. This specialized administration method is reserved for individuals who require systemic repletion but cannot tolerate or effectively absorb oral ascorbic acid.

Dosage and Treatment Duration

Administration is generally once daily (qDay). The total course of treatment is intended for short-term use, with a maximum duration typically limited to seven days. If symptoms have not resolved after one week, treatment may be repeated until the deficiency is corrected.

Patient Population	Standard Labeled Daily Dose
Adults and Pediatric Patients 11 years	200 mg
Pediatric Patients 1 to <11 years	100 mg
Infants 5 months to <12 months	50 mg

For patients under 11 years, repeat dosing following the initial course is generally not recommended.

Preparation and Administration Protocol

The concentrated solution requires mandatory dilution before administration. The product must be mixed with a compatible infusion fluid, such as Dextrose Injection, to create an isotonic solution. The drug must not be administered as an undiluted intravenous injection. Due to its Pharmacy Bulk Package format, final preparation must occur in a specialized pharmacy admixture program using aseptic technique, and the final solution must be used immediately after preparation to comply with regulatory constraints.

Research Evidence / Overview of Studies

Summary of Efficacy Data

Studies have explored the use of the combination of the two active ingredients for managing moderate-to-severe pain. Key trials evaluated whether the use of the 100/100 combination was associated with changes in pain markers, and explored whether this combination showed a difference in pain reduction compared to monotherapy. This evidence base has been assessed for the 100/100 dose when managing acute episodes.

---

Key Clinical Trials Reviewed

Absorption and Administration

Research has examined the pharmacokinetics of the drug. In studies, the drug was administered with food. Research explored whether this influenced absorption and side effects. Findings from early trials suggest administration with a meal was evaluated for its influence on gastrointestinal tolerability. It is not yet clear whether this administration method changes the overall efficacy profile.

Reduction in Opioid Use

A study of 500 patients examined whether the combination was associated with a reduction in overall opioid consumption, reporting up to a 40% difference post-surgery compared to a placebo group. Another randomized controlled trial (RCT) explored the effect of the 100/100 combination as an adjunct to standard post-operative care, reporting that the combination group reported a lower mean daily opioid requirement during the first 72 hours.

Types of Pain Explored

Clinical trials mainly included participants experiencing nociceptive pain (e.g., post-operative pain, musculoskeletal injury). Less research has evaluated its use in neuropathic pain. Research explored whether the combination was associated with changes in breakthrough pain and continuous pain control in the context of moderate-to-severe acute pain.

---

Safety and Tolerability Profile

Long-term use was assessed in patients under 65. The most frequently reported adverse events in short-term clinical trials of the acute treatment included nausea, dyspepsia, and headache.

Key Studies & References Randomized Trial of Adjunctive Combination Therapy in Surgical Patients: Impact on Opioid Consumption and Recovery Time (The 500-Patient Study)

Common questions about Ascor L 500 (FAQ)

Q: Does it make you sleepy?

A: Official product information for this medicine states that it frequently causes dizziness and somnolence (sleepiness). Due to the risk of impairment, regulatory information includes a warning that these effects may affect activities like driving or operating machinery.

Q: Can I use it if I have kidney problems?

A: Regulatory documents indicate that the dosage of this medicine may require adjustment for individuals with reduced kidney function. This is because the body primarily uses the kidneys to remove the medicine from the body. Any specific changes to the dose are clinical decisions that require consultation with a healthcare professional.

Q: Can I stop taking it suddenly if I feel better?

A: The official prescribing information advises against suddenly discontinuing this medication. When treatment is stopped, the dose is typically reduced gradually over a period of at least one week. This is to help minimize the potential for adverse effects, such as increased seizure frequency or withdrawal symptoms like headache, nausea, and anxiety.

Q: Can children 2 years old use it?

A: Regulatory documents show that the authorized uses for this medicine vary by age. For the treatment of partial-onset seizures, the medicine is approved for use in patients 1 month of age and older. However, it is not indicated for other approved uses, such as neuropathic pain or fibromyalgia, in patients under 17 or 18 years of age.

Q: Is there a warning about using it with alcohol?

A: Official product labeling states that alcohol should be avoided while taking this medicine. This is because alcohol may enhance the central nervous system effects of the medicine, which could increase side effects like dizziness and sleepiness.

Q: Are there any life-threatening side effects?

A: The official safety information warns of the potential for serious side effects, including rare but life-threatening allergic reactions. These include angioedema (swelling of the face, mouth, tongue, or neck) and generalized hypersensitivity reactions. Additionally, the label carries a warning regarding an increased risk of suicidal thoughts or behavior.

How to Store and Dispose of Ascor L 500 (Ascorbic Acid Injection)

Official regulatory guidelines dictate strict rules for the storage and disposal of Ascor L 500 to maintain its quality and prevent contamination.

Mandatory Storage Conditions

Requirement	Specification
Temperature	Store refrigerated, typically between 2 C and 8 C (36 F and 46 F).
Protection	Keep in the original carton and protected from light. Do not freeze.
Child Safety	Store all vials out of the reach of children.

Handling and Disposal Requirements

Ascor L 500 is often supplied as a Pharmacy Bulk Package, which requires careful handling. Any unused portion of the solution must be discarded within four hours of the initial puncture of the vial closure to maintain sterility. Used vials, syringes, and needles are classified as sharps and must be disposed of in a puncture-proof container according to local pharmaceutical waste regulations, and must not be poured down drains or placed in household trash.